- $51.49m
- $50.21m
- $40.93m
Brief: Ruling By German Social Court Supports MyoPro Reimbursement By Nation's Statutory Health Insurance System
Brief: Myomo Reports Third Quarter 2022 Financial Results
Brief: Myomo Receives Order To Support MyoPro Clinical Trial
Brief: Myomo Reports Second Quarter 2022 Financial Results
Brief: Myomo Expects Q2 Revenue To Be $3.4 Mln To $3.6 Mln
U.S. RESEARCH ROUNDUP- Cooper Companies, Moody's, Seagen
Brief: Myomo Reports First Quarter 2022 Financial Results
Brief: Myomo Reports Progress With China Joint Venture, Receives Partial Payment Of Technology License Fee
Brief: Myomo Reports Fourth Quarter And Full Year 2021 Financial Results
Brief: Myomo Strengthens Intellectual Property Portfolio With Receipt Of Key Patent In Japan
Brief: Myomo Provides Update On Myopro Insurance Reimbursement
Brief: Myomo Amends China Joint Venture Agreement, Executes Technology And Trademark License Agreement
Brief: Myomo Posts Q3 Loss Per Share Of $0.36
Brief: Myomo Inc - Entered Into An Amendment No. 1 To Company's Existing Fabrication And Services Agreement With Geauga Rehabilitation Engineering
Brief: Myomo Inc Announces Granting Of Patents In China And Hong Kong
U.S. RESEARCH ROUNDUP-Adobe, Goodrx Holdings, PG&E
Brief: Myomo - Colliers Securities Raises Target Price To $17
Myomo surges on Q2 revenue beat
Brief: Myomo Posts Q2 Loss Per Share Of $0.46